The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
The supplemental biologics license application (sBLA) for enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) has received priority review from the FDA. The combination is being considered as frontline treatment for patients with locally advanced or metastatic urothelial cancer.
The designation is based on findings from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856), which demonstrated that the combination led to a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared with platinum-containing chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer.2 Additionally, the safety profile of the regimen was in line with that previously reported with the combination, and no new safety signals occurred.1
The target action date is May 9, 2024, under the Prescription Drug User Fee Act. If approved, the combination would be the first treatment regimen for patients with previously untreated locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility.
“Through our clinical development program, data have consistently shown the impact of combining enfortumab vedotin with pembrolizumab for advanced bladder cancer. The FDA’s acceptance of our application is a critical step in our work as we seek to deliver this combination to more patients who currently have few treatment options at the advanced stage,” Roger Dansey, MD, president of Research and Development at Seagen, stated in a news release.
In February 2020, the combination received breakthrough therapy designation from the FDA as frontline therapy for cisplatin-ineligible patients,3 and by December 2022, the sBLA for the regimen had received priority review designation for this population.3 and by December 2022, the sBLA for the regimen had received priority review designation for this population.4 In April 2023, the FDA granted accelerated approval to the combination for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy based on response rate and durability of response data from the phase 1b/2 EV-103/KEYNOTE-869 trial (NCT03288545).5
The EV-302 trial was designed to serve as the confirmatory trial for the US accelerated approval and the basis for other global regulatory submissions, as well as support the expanded indication into the cisplatin-eligible patient population.
“We look forward to the FDA’s review of this application, which, if approved, will convert the accelerated approval of the combination based on results from the EV-103 study to standard approval for all first-line locally advanced or metastatic urothelial cancer patients, expanding the indication to cisplatin eligible patients. These patients have a critical need for innovative new therapies, as chemotherapy has been the standard of care for over 30 years. We are committed to delivering on our goal of helping patients with advanced urothelial cancer live longer,” Ahsan Arozullah, MD, MPH, senior vice president and head of Oncology Development at Astellas, said in the release.
The combination of enfortumab vedotin and pembrolizumab is also under investigation in patients with muscle-invasive bladder cancer in the phase 3 EV-304/KEYNOTE-B15 (NCT04700124) and EV-303/KEYNOTE-905 (NCT03924895) trials.
Additionally, the open-label, multicenter, multi-cohort, phase 2 EV-202 trial (NCT04225117) is evaluating enfortumab vedotin alone in patients with previously treated advanced solid tumors. The study also has a cohort that is evaluating enfortumab vedotin plus pembrolizumab in patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma.